Search results
Results From The WOW.Com Content Network
1. 2015. Pfizer. Allergan, plc. 160. 206. In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation). However, this deal was cancelled in April 2016 due to new US tax inversion rules. [ 12][ 13] Had this transaction been completed, this would have been the largest within this industry.
The only part of the process that pharma-tech companies like Recursion aim to improve, though, is near the beginning. For a company that promises to speed up the drug development process ...
Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday.
IQVIA, formerly Quintiles and IMS Health, Inc., [6] is an American Fortune 500 and S&P 500 multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development, professional consulting and commercial outsourcing services, focused primarily on Phase I ...
This is the first time in 14 years that the commission had brought a case against a pharmaceutical merger. The lawsuit involved Horizon’s Tepezza, used to treat thyroid eye disease, and Kystexxa ...
Pfizer Inc. ( / ˈfaɪzər / FY-zər) [3] is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).
Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic syndrome (aHUS) and ...
July 2, 2024 at 6:23 PM. (Reuters) - Drug developer Semnur Pharmaceuticals said on Tuesday it has signed a letter of intent to go public through a merger with special purpose acquisition company ...